

Cardiff and Vale (UHB) corporate Medicines Management Group (c MMG)

Shared Care and Shared care/Near Patient Testing drugs (January 2017)

Note – unless Children are specifically mentioned, Shared Care protocols relate to adults only.

Drug	Indication	Protocol Number
Amiodarone	Severe cardiac rhythm disorders	CV 44
Apomorphine	Disabling motor fluctuations in Parkinson's disease	CV 02
Atomoxetine	Attention Deficit Hyperactivity Disorder (ADHD), Hyperkinetic Disorder (HKD) in children 6 years and older, adolescents and adults who began treatment during childhood	CV 46
Azathioprine	Autoimmune conditions usually where corticosteroid therapy alone provides inadequate control.	CV 51
Azathioprine	Liver transplantation	CV 04
Ciclosporin	Severe Psoriasis	CV 26
Ciclosporin	Rheumatoid arthritis	CV 29
Dalteparin	Dalteparin for patients with VTE and a solid tumour	CV 56
Disulfiram	Maintenance of abstinence in alcohol	CV20
Dornase alfa	Cystic fibrosis	CV 38
Erythropoietin [EPO alfa / beta]	Anaemia of chronic renal failure in children	CV 08
Ketamine	Pain in a palliative care setting not responding to opioids and adjuvant therapy.	CV 10
Lanreotide	Acromegaly, carcinoid syndrome and other peptide hormone secreting tumours	CV 40
Leflunomide	Rheumatoid arthritis and Psoriatic arthritis	CV 11
Leuprorelin	Precocious puberty	CV 22
Lisdexamfetamine	Attention deficit hyperactivity disorder (ADHD) as part of a comprehensive treatment programme in children aged 6 years of age and over.	CV 57
Lithium	Prophylaxis of mania, bipolar disorder, recurrent depression	CV 12
Melatonin	For children and adolescents (up to and including 18 years) with significant sleep onset difficulties	CV 54
6-Mercaptopurine	Inflammatory Bowel Disease	CV 25
Methadone	Pain requiring methadone for control	CV 14
Methotrexate	Rheumatoid arthritis and various auto-immune conditions usually when corticosteroid therapy alone provides inadequate control	CV 55
Methylphenidate	ADHD, Hyperkinetic disorder	CV 42
Mycophenolate mofetil	Various conditions which characteristically respond to immune suppressive therapy.	CV 53
Octreotide LAR	Acromegaly, carcinoid syndrome and other peptide hormone secreting tumours	CV 33
Octreotide	Palliative care	CV 16
Penicillamine	Rheumatoid arthritis	CV 17
Riluzole	Motor neurone disease (MND)	CV 39
Sodium aurothiomalate	Rheumatoid arthritis	CV 19
Somatropin	Growth hormone in children	CV 27
Somatropin	Adult Growth disorders	CV 34
Sulfasalazine	Inflammatory Bowel Disease	CV 41
Sulfasalazine	Rheumatoid arthritis	CV 21
Tacrolimus	Liver transplantation	CV 43

Tobramycin nebuliser solution	Chronic colonisation with <i>pseudomonas aeruginosa</i> in Cystic fibrosis	CV 48
Triptorelin	Precocious puberty	CV 23

